Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SELLAS Life Sciences GroupSLS +1.56%28 3-Year FCF Growth Rate is 43.70% as of Jun. 2026, which is 4% above its 10-year median of 42.05. GuruFocus rates SLS with a GF Scoreâ„¢ of 28/100. Among 1,105 Biotechnology companies, SELLAS Life Sciences Group ranks better than 77.65% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 43.70% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 27.70% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 61.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of SELLAS Life Sciences Group was 82.30% per year. The lowest was -0.60% per year. And the median was 42.05% per year.
SELLAS Life Sciences Group (NAS:SLS) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
SELLAS Life Sciences Group 3-Year FCF Growth Rate Related Terms
SLS vs ATAI, VRDN, NRIX: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, SELLAS Life Sciences Group's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's 3-Year FCF Growth Rate falls into.
SELLAS Life Sciences Group 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 43.70% mean?
SELLAS Life Sciences Group (SLS) has a 3-Year FCF Growth Rate of 43.70% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for SELLAS Life Sciences Group and its competitors. This is near median its historical median of 42.05. According to the industry distribution chart, SELLAS Life Sciences Group ranks #247 out of 1105 companies in the Biotechnology industry, placing it in the top 22.4%.
Is SELLAS Life Sciences Group's 3-Year FCF Growth Rate too high?
SELLAS Life Sciences Group's current 3-Year FCF Growth Rate of 43.70% is near median its 10-year median of 42.05. The Biotechnology industry median 3-Year FCF Growth Rate is 19.30. SELLAS Life Sciences Group's value of 43.70% is 126.4% above this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #247 out of 1105 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's 3-Year FCF Growth Rate compare to ATAI and VRDN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #247 out of 1105 companies for 3-Year FCF Growth Rate. This places SELLAS Life Sciences Group in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year FCF Growth Rate is 19.30. SELLAS Life Sciences Group's value of 43.70% is 126.4% above this benchmark. While the company's 10-year median is 42.05 vs. the industry median of 19.30, SELLAS Life Sciences Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.30, based on 1,105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current 3-Year FCF Growth Rate of 43.70% is 126.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current 3-Year FCF Growth Rate is 43.70%, which is near median its own 10-year median of 42.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current 3-Year FCF Growth Rate of 43.70%. The current 3-Year FCF Growth Rate is 43.70%, which is near median its 10-year median of 42.05 and 126.4% above the Biotechnology industry median of 19.30. SELLAS Life Sciences Group's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current 3-Year FCF Growth Rate is 43.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
28GF Score
Get the complete analysis for SLS
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
